An Open Label, Single-Centre, Pilot Study for Radiosensitization of Everolimus With External Beam Radiation Therapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis
Approximately 50% of patients with neuroendocrine cancers present with metastasis, a vast
majority to the liver. In such patients, one treatment option for liver-directed therapy is
surgical resection. However, a significant proportion of patients are not eligible for
resection because of patient factors (age, comorbidities) or tumour-related factors.
There have been scant data on the utility of EBRT (external-beam radiation therapy) and SABR
(stereotactic ablative radiation therapy) for metastatic neuroendocrine tumours of the liver. This
study will measure the effects of concurrent everolimus with external-beam radiation therapy to
the liver for metastatic neuroendocrine New methods of tumour assessment are needed in NETs.
Three new techniques are being developed at the Sunnybrook Research Institute to assess
tumour response to treatment: (1) contrast enhanced ultrasound; (2) perfusion CT; and (3)
perfusion MRI. These methods are devised to measure tumour perfusion and blood flow as
response indicators and can measure cell death non-invasively.
1. Concurrent everolimus given with external-beam radiation therapy to the liver for metastatic
neuroendocrine tumours of the liver will enhance the efficacy of radiation therapy and add
little, if any, toxicity
2. New radiological measures of CEUS and DCE-CT are effective measure to delineate tumour
response in NETs.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society